Evidence map›Paper›PMID 41004259›Full record

ArticleAntimicrobial agents and chemotherapy2025

Immunocompromised patients with persistent SARS-CoV-2 viral shedding ≥8 weeks, clinical outcomes, and virological dynamics: a retrospective multicenter cohort study, 2020-2024.

Clémentine de La Porte des Vaux, Nicolas Veyrenche, Kevin Da Silva, Nathalie Chavarot, Marianne Burgard, Olivier Paccoud, Florence Runyo, Margaux Garzaro, Claire Rouzaud, Alexandra Serris and 8 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The effects of SARS-CoV-2 on bone homeostasis.Frontiers in endocrinology · 2026
    Review
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Clémentine de La Porte des VauxDepartment of Infectious and Tropical Diseases, Hôpital Necker Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), IHU Imagine, Université Paris Cité, Paris, France.ORCID 0000-0002-5472-7032
Nicolas Veyrenche *Department of Virology, Hôpital Necker Enfants Malades, APHP, Université Paris Cité, Paris, France.
Kevin Da Silva *National Reference Center for Respiratory Viral Infections, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-3022-5361
Nathalie ChavarotDepartment of Nephrology and Kidney Transplantation, European Hospital George Pompidou, APHP, Université Paris Cité, Paris, France.
Marianne BurgardDepartment of Virology, Hôpital Necker Enfants Malades, APHP, Université Paris Cité, Paris, France.
Olivier PaccoudDepartment of Infectious and Tropical Diseases, Hôpital Necker Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), IHU Imagine, Université Paris Cité, Paris, France.
Florence RunyoDepartment of Infectious and Tropical Diseases, Hôpital Necker Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), IHU Imagine, Université Paris Cité, Paris, France.
Margaux GarzaroDepartment of Infectious and Tropical Diseases, Hôpital Necker Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), IHU Imagine, Université Paris Cité, Paris, France.
Claire RouzaudDepartment of Infectious and Tropical Diseases, Hôpital Necker Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), IHU Imagine, Université Paris Cité, Paris, France.
Alexandra SerrisDepartment of Infectious and Tropical Diseases, Hôpital Necker Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), IHU Imagine, Université Paris Cité, Paris, France.
Damien VimpereIntensive Care Unit, Hospital Necker-Enfants Malades, APHP, Université Paris Cité, Paris, France.
Dany AnglicheauDepartment of Nephrology and Kidney Transplantation, Hospital Necker-Enfants Malades, APHP, Université Paris Cité, Paris, France.
Luc MouthonDepartment of Internal Medicine, Hôpital Cochin, APHP, Université Paris Cité, Paris, France.
Olivier HermineDepartment of Hematology, Hospital Necker-Enfants Malades, APHP, Université Paris Cité, Paris, France.
Marie-Anne Rameix-Welti *National Reference Center for Respiratory Viral Infections, Institut Pasteur, Université Paris Cité, Paris, France.
Fanny Lanternier *Department of Infectious and Tropical Diseases, Hôpital Necker Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), IHU Imagine, Université Paris Cité, Paris, France.
Olivier Lortholary *Department of Infectious and Tropical Diseases, Hôpital Necker Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), IHU Imagine, Université Paris Cité, Paris, France.
Cléa MelenotteDepartment of Infectious and Tropical Diseases, Hôpital Necker Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), IHU Imagine, Université Paris Cité, Paris, France.ORCID 0000-0003-3159-1061

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunocompromised patients (ICPs) infected with SARS-CoV-2 are at higher risk of severe illness. Some experience persistent viral shedding beyond eight weeks, which is associated with increased mortality and invasive fungal infections. However, data on the clinical profile, treatment impact, and standardized management for these patients remain limited. We conducted a retrospective cohort study at Groupe Hospitalier Paris Centre between March 1, 2020, and February 10, 2024. We assessed symptomatic ICPs with persistent SARS-CoV-2 shedding (>8 weeks), analyzing clinical progression, time to viral clearance, and emergence of resistance mutations in relation to treatment regimens. Fifty-three patients were included: 53% were solid organ transplant (SOT) recipients, 42% had hematological malignancies (HMs), and 5% had other immunosuppressive conditions. Severe infections occurred in 32%, 91% required hospitalization, and 17% (

Indexed as

Antiviral AgentsCOVID-19Immunocompromised HostSARS-CoV-2Virus SheddingAdenosine MonophosphateAdultAgedAlanineAntibodies, MonoclonalCOVID-19 Drug TreatmentCOVID-19 SerotherapyFemaleHumansMaleMiddle AgedAdenosine MonophosphateAlanineAntibodies, MonoclonalAntiviral Agentsremdesivirdirect antiviralsimmunocompromised patientspersistent SARS-CoV-2 sheddingsolid organ transplant (SOT)viral resistance

Identifiers

PMID41004259
PMCPMC12587602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.